Medulloblastoma

5 trials 2 recruiting MedDRA PT
5 Registered trials
2 Recruiting
5 Unique sponsors
3 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
CDK inhibitor 1 substance
Phase III: 1 Phase II: 3 Phase I/II: 1

Filter these 5 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 5 trials

Phase III

1 trial
  • The University Of Birmingham Academic
    LOMUSTINE
    2024-510578-25-00 10 countries 2021 n=407
    Recruiting

Phase II

3 trials
  • Azienda Ospedaliera Universitaria Meyer IRCCS Academic
    IMP not specified
    2024-518964-11-01 1 country 2025 n=18
    Ended
  • CHRU De Nancy Academic
    IMP not specified
    2024-513243-85-00 1 country 2023 n=45
    Recruiting
  • European Organisation For Research And Treatment Of Cancer Academic
    SONIDEGIB
    2023-506193-12-00 1 country 2022 n=32
    Ended

Phase I/II

1 trial
  • Novartis Pharma AG Commercial
    RIBOCICLIB
    2024-512095-35-00 7 countries 2022 n=49
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Novartis Pharma AG Commercial 1 Phase I/II 0
Azienda Ospedaliera Universitaria Meyer IRCCS Academic 1 Phase II 0
CHRU De Nancy Academic 1 Phase II 1
European Organisation For Research And Treatment Of Cancer Academic 1 Phase II 0
The University Of Birmingham Academic 1 Phase III 1
New trials by year
2021
1
2022
2
2023
1
2025
1
← All indication landscapes